Discover how GLP-1 receptor therapy for cardiometabolic approaches can revolutionize treatment strategies for patients.

Abstract

Welcome to our educational overview on the groundbreaking shifts in managing cardiometabolic health. In this post, I will guide you through the complexities of managing type 2 diabetes, cardiovascular disease, and chronic kidney disease, particularly when standard treatments like basal insulin are no longer sufficient. We will explore the pivotal research that prompted a move away from a solely glucose-centric model to a comprehensive, risk-reduction strategy. I’ll delve into the mechanisms of two key classes of medications, SGLT2 inhibitors and GLP-1 receptor agonists, and explain how they offer profound cardiovascular and renal protection. We will examine the challenge of over-basalization, in which increasing insulin doses yield diminishing returns, and discuss why GLP-1 agonists are now a superior alternative to prandial insulin for many patients. Furthermore, I will explain how our multidisciplinary team at Injury Medical Clinic, under the collaborative guidance of our Medical Director, Dr. Maria Guadalupe Cardenas, MD, an internist with over 40 years of experience, integrates these medical advancements with integrative chiropractic care, functional medicine, and personalized rehabilitation. This holistic approach allows us to address the systemic nature of these conditions, managing not just symptoms but the underlying physiological imbalances to optimize our patients’ long-term health and well-being.

Our Integrative Approach at Injury Medical Clinic

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we pride ourselves on a forward-thinking, multidisciplinary model of patient care. I am Dr. Alex Jimenez, and my extensive training in chiropractic, advanced practice nursing, and functional medicine allows me to view patient health through a multifaceted lens. This perspective is powerfully complemented by the medical oversight of our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) and brings over four decades of clinical wisdom to our practice in El Paso, Texas.

This collaborative structure, where an MD provides medical direction alongside a chiropractor, is a cornerstone of modern integrative and injury care clinics. It enables us to create a seamless fusion of care that addresses both the structural and metabolic aspects of health. Our services include:

• Integrative Chiropractic Care: We focus on optimizing neuromusculoskeletal function, which is crucial for mobility, reducing systemic inflammation, and improving overall physiological resilience.
• Medical Oversight (Dr. Cardenas): Cardenas guides our clinical protocols, manages pharmacotherapy when necessary, and ensures our integrative strategies align with the highest standards of conventional medical care.
• Functional Medicine: We investigate the root causes of chronic disease, analyzing diet, lifestyle, genetics, and environmental factors to develop personalized treatment plans.
• Personal Injury & Rehabilitation: We provide comprehensive care for individuals recovering from injuries, integrating physical therapies with metabolic support to accelerate healing and prevent long-term complications.

This synergistic approach is particularly vital for patients with complex cardiometabolic conditions, as it allows us to manage their health holistically, from spinal alignment and nervous system function to blood sugar regulation and cardiovascular risk reduction.

The Paradigm Shift: Beyond Glucose Control

For decades, the primary goal in managing type 2 diabetes was to lower blood glucose levels as aggressively as possible. However, we have come to understand that this is only one piece of a much larger puzzle. Patients with type 2 diabetes face an exceptionally high risk for atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death in this population.

Consider this staggering statistic: over 70% of individuals with diabetes over the age of 65 will likely die from heart disease or stroke. Their prognosis following a heart attack or stroke is significantly poorer than in individuals without diabetes, and this remains true even when their blood sugar is well-controlled. This applies to both type 1 and type 2 diabetes.

This reality has forced a profound shift in our thinking. Leading global health organizations, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and Kidney Disease: Improving Global Outcomes (KDIGO), have now reached a landmark consensus. For the first time, their guidelines are aligned, advocating for a new paradigm that prioritizes comprehensive risk reduction over singular glucose management. This involves concurrently addressing:

• Blood Pressure
• Cholesterol Levels
• Blood Glucose
• Body Weight
• Physical Activity
• Smoking Cessation

This collaborative vision means we no longer view these conditions through isolated lenses but as an interconnected web of cardiometabolic and renal dysfunction.

The Turning Point: FDA Mandates and Surprising Discoveries

How did we arrive at this new understanding? The journey began in 2008, when the U.S. Food and Drug Administration (FDA) issued a crucial guidance document. It mandated that all new anti-diabetic agents undergo long-term Cardiovascular Outcomes Trials (CVOTs). This was a direct response to past experiences where certain medications, like rosiglitazone (Avandia) and Vioxx, were later found to increase cardiovascular harm despite their intended benefits.

Prior studies were often too short, underpowered, or poorly designed to detect these risks. The new FDA mandate required pharmaceutical companies to conduct large, well-designed, placebo-controlled trials to rule out an unacceptable increase in Major Adverse Cardiovascular Events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke.

What happened next was revolutionary. These trials, designed primarily to prove safety, began to reveal something unexpected: certain drug classesdidn’tt avoid harm—they actively conferred significant cardiovascular and renal benefits. This was a watershed moment in medicine.

• 2015: The EMPA-REG OUTCOME trial for empagliflozin (Jardiance), an SGLT2 inhibitor, shocked the medical community by demonstrating a significant reduction in MACE, cardiovascular death, and hospitalization for heart failure (Zinman et al., 2015).
• 2016: The LEADER trial for liraglutide (Victoza), a GLP-1 receptor agonist, followed suit, also showing profound cardiovascular protection (Marso et al., 2016).

These surprising results from over 18 CVOTs published by 2020 fundamentally altered our treatment guidelines, leading us directly to the risk-based algorithms we use today.

Decoding the New ADA Treatment Algorithm

The American Diabetes Association (ADA) has developed a clear, risk-stratified algorithm that reflects this new paradigm. It emphasizes that healthy lifestyle behaviors remain the foundation of care and are recommended at every patient visit. The algorithm then splits into two primary pathways:

1. Right-Hand Side (Routine Risk): This path is for patients early in their diagnosis with no established heart disease, kidney disease, or major cardiovascular risk factors. Here, the focus is on achieving glycemic targets and managing general health.
2. Left-Hand Side (High Risk): This path is for patients with established ASCVD, high risk for ASCVD, heart failure, or chronic kidney disease (CKD). For these individuals, the guidelines now recommend specific medication classes as first-line therapy independent of their baseline A1c or metformin use.

• • For ASCVD or High ASCVD Risk: The preferred agent is a GLP-1 receptor agonist with proven benefit, followed by an SGLT2 inhibitor if needed or contraindicated.
  • For Heart Failure (especially HFrEF and HFpEF): The first-line choice is an SGLT2 inhibitor.
  • For Chronic Kidney Disease: The preferred agent is an SGLT2 inhibitor, now followed by specific GLP-1 receptor agonists that have also demonstrated nephroprotective benefits.

Crucially, these drug classes are not mutually exclusive. In my clinical experience, using them in combination—an SGLT2 inhibitor with a GLP-1 receptor agonist—often provides synergistic benefits for our highest-risk patients, addressing multiple pathological pathways simultaneously.

Deep Dive: The SGLT2 Inhibitor Class

Sodium-glucose cotransporter-2 (SGLT2) inhibitors work by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine. While this mechanism lowers blood sugar, their profound benefits extend far beyond glycemic control. Let’s explore the CVOTs and the mechanisms behind their success.

Key Cardiovascular Outcomes Trials for SGLT2 Inhibitors

• EMPA-REG OUTCOME (empagliflozin/Jardiance): Showed highly significant reductions in MACE, cardiovascular death, and hospitalization for heart failure.
• CANVAS Program (canagliflozin/Invokana): Demonstrated significant reductions in MACE and hospitalization for heart failure (Neal et al., 2017).
• DECLARE-TIMI 58 (dapagliflozin/Farxiga): While not as strong on MACE, it showed a very powerful reduction in the risk of hospitalization for heart failure (Wiviott et al., 2019).
• VERTIS-CV (ertugliflozin/Steglatro): Also achieved statistical significance for reducing hospitalization for heart failure.

A 30% relative risk reduction in hospitalization for heart failure is a common and powerful finding across this class, making these drugs a cornerstone of modern cardiology and nephrology.

The Multifaceted Mechanisms of SGLT2 Inhibitors

Why are these drugs so beneficial? The effects are systemic and address multiple underlying dysfunctions seen in cardiometabolic disease.

• Hemodynamic Effects:

• • Reduced Blood Pressure: A modest but significant drop of about 5 mmHg in systolic pressure.
  • Natriuresis and Diuresis: They promote the excretion of sodium and water, acting as a gentle diuretic. This reduces blood volume and cardiac preload, easing the workload on the heart.

• Renal Protection:

• • Reduced Glomerular Pressure: By constricting the afferent arteriole in the kidney’s nephron, they lower the intense pressure within the glomeruli. This is believed to be the primary mechanism protecting the kidneys from the progressive damage seen in diabetic nephropathy.

• Metabolic and Cellular Benefits:

• • Modest Weight Loss: Patients typically lose 5-7 pounds, a welcome benefit compared to older diabetes drugs that cause weight gain.
  • Improved Myocardial Energetics: The heart functions more efficiently in mild ketosis. SGLT2 inhibitors slightly increase ketone body levels, providing a “superfuel” for the myocardium.
  • Reduced Inflammation and Oxidative Stress: They help quell the chronic, low-grade inflammation and oxidative damage that drive plaque formation and endothelial dysfunction.
  • Plaque Stabilization: They contribute to more stable atherosclerotic plaques, reducing the risk of rupture and of acute events such as heart attack.

These pleiotropic effects explain why SGLT2 inhibitors are now used in patients with and without diabetes for the management of heart failure and chronic kidney disease.

Landmark Trials in Heart Failure and Renal Disease

The benefits of SGLT2 inhibitors were so profound that dedicated trials were launched to study their effects specifically on heart failure and kidney disease.

• Heart Failure Trials:

• • DAPA-HF & EMPEROR-Reduced: These trials studied patients with heart failure with reduced ejection fraction (HFrEF). Both dapagliflozin and empagliflozin showed a remarkable 25-26% relative risk reduction in cardiovascular death or hospitalization for heart failure, regardless of diabetes status (McMurray et al., 2019).
  • EMPEROR-Preserved: This was a groundbreaking trial for patients with heart failure with preserved ejection fraction (HFpEF)—a notoriously difficult-to-treat condition common in women and obese individuals with diabetes. Empagliflozin was the first drug to show a meaningful 21% reduction in the primary endpoint of cardiovascular death or hospitalization for heart failure (Anker et al., 2021).

• Renal Trials:

• • DAPA-CKD & EMPA-KIDNEY: Both trials were stopped early due to overwhelming efficacy. They demonstrated a 39-47% relative risk reduction in the progression of nephropathy.
  • CREDENCE (canagliflozin): Also showed a 40% reduction in renal-specific outcomes.

Understanding Over-Basalization in Type 2 Diabetes

Let’s explore a common scenario I see in my practice. Imagine a patient, let’s call him Tony.

Patient Profile: “Tony”

• Age: 62-year-old male
• Diagnosis: Type 2 diabetes for 11 years
• Recent A1C: 8.2% (well above the target goal)
• Comorbidities: Hyperlipidemia, hypertension, proteinuria (protein in the urine, indicating kidney stress)
• Current Medications:

• • Degludec (basal insulin): 65 units daily
  • Metformin: 1,000 mg twice daily
  • SGLT2 inhibitor: Daily
  • Statin: Daily
  • ARB (angiotensin receptor blocker): Daily

• Physicals: Weight 220 lbs, Height 5’9”, BMI 32.5 (obese)
• Blood Glucose Readings:

• • Fasting (morning): 110-150 mg/dL
  • Postprandial (after meals/bedtime): 160-200 mg/dL

Tony’s case perfectly illustrates a challenge we call “over-basalization.” He is on a significant dose of basal insulin, yet his A1C and post-meal blood sugars remain dangerously high. This is a critical juncture where simply increasing the insulin dose is not the answer and can, in fact, be counterproductive.

Research and pharmacokinetic studies on obese patients with type 2 diabetes have revealed a “ceiling effect” for basal insulin. At doses greater than 0.5 units per kilogram of body weight per day, the additional benefit on blood sugar control becomes modest at best. For Tony, who weighs 100 kg (220 lbs), this threshold is around 50 units of insulin. He is already taking 65 units, pushing him past this point of diminishing returns.

The Defining Signs of Over-Basalization

How do we identify over-basalization in a clinical setting? There are several key indicators:

• High Insulin Dose: The patient is taking more than 5 units/kg/day of basal insulin.
• Elevated Post-Meal Glucose: Blood sugar levels consistently exceed 180 mg/dL after meals.
• Uncontrolled A1C Despite Good Fasting Glucose: The overall A1C remains high even if morning blood sugar levels are within an acceptable range.
• Large Bedtime-to-Morning Glucose Drop: The difference between the bedtime blood sugar reading and the fasting morning reading is greater than 50 mg/dL. Tony’s readings fit this pattern, indicating his basal insulin is working overnight but failing to control his glucose throughout the day.

This situation demands a strategic shift. We must look beyond just adding more insulin.

Rethinking the Next Step: Prandial Insulin vs. GLP-1 Agonists

When a patient like Tony is not at goal on basal insulin, the traditional next step has often been to add prandial (mealtime) insulin. This involves taking a rapid-acting insulin shot before the largest meal of the day to counteract the glucose spike from the meal. While this can be effective for lowering A1C, it comes with significant downsides:

1. Weight Gain: Insulin is an anabolic hormone that promotes fat storage. For a patient like Tony, who is already struggling with obesity, further weight gain can worsen insulin resistance and overall health.
2. Hypoglycemia Risk: Adding another insulin injection dramatically increases the risk of hypoglycemia (dangerously low blood sugar), a condition that can be frightening and, in severe cases, life-threatening.

Fortunately, modern medicine has provided us with a more intelligent and beneficial alternative: GLP-1 receptor agonists. The American Diabetes Association (ADA) guidelines now recommend considering a GLP-1 receptor agonist before initiating prandial insulin in most patients who need to intensify their treatment beyond basal insulin.

Understanding the Incretin System: Why GLP-1 and GIP Matter

As a clinician in an integrative practice, I often start by explaining the core physiology. The incretin concept emerged when researchers observed that oral glucose produced a more powerful blood glucose-lowering effect than intravenous glucose. That led to the discovery of gut-derived hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—which are released when food reaches the stomach and small intestine, triggering pancreatic insulin secretion in a glucose-dependent manner and suppressing glucagon when appropriate.

• Key incretin physiology:

• • GLP-1 and GIP are secreted by enteroendocrine cells in the gut in response to nutrient exposure.
  • They enhance insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia when used alone.
  • They suppress glucagon, reducing hepatic glucose output.
  • GLP-1 slows gastric emptying, increases satiety, and supports weight loss.

In type 2 diabetes, the incretin effect is blunted: GLP-1 secretion and responsiveness are reduced. That physiologic defect contributes to hyperglycemia, poor satiety, and excess caloric intake. This clear mechanistic impairment explains why GLP-1 receptor agonists (GLP-1 RAs) help restore the physiologic balance—supporting insulin release when needed, moderating glucagon, slowing gastric emptying to curb appetite, and improving postprandial glycemia.

From a pharmacologic standpoint, DPP-4 inhibitors are designed to prevent the rapid enzymatic breakdown of native incretins by the DPP-4 enzyme, thereby extending the action of endogenous GLP-1/GIP. While DPP-4 inhibitors are weight-neutral and generally well tolerated, GLP-1 RAs typically demonstrate stronger effects on A1C reduction, weight loss, and cardiovascular outcomes.

The Power of GLP-1 Receptor Agonists: More Than Just Glucose Control

So why are GLP-1 receptor agonists such game-changers? These medications work by mimicking the effects of a natural hormone in our body called glucagon-like peptide-1. The mechanisms of GLP-1 agonists are mumultifacetednd exert broad metabolic actions:

• Pancreas: They increase glucose-dependent insulin secretion and beta-cell workload efficiency, stimulating the pancreas to release insulin only when blood sugar is high. This intelligent mechanism significantly reduces the risk of hypoglycemia compared to direct insulin injections. They also suppress glucagon when glucose is elevated.
• GI tract: They slow gastric emptying, which leads to a feeling of fullness (satiety), blunts the sharp spike in blood sugar after a meal, and curbs caloric intake.
• Central nervous system: They act on the brain to reduce appetite and food cravings, enhancing satiety signaling.
• Cardiovascular system: They lower blood pressure, reduce cardiac filling pressures, and may improve myocardial metabolism.
• Liver and kidney: They improve steatosis parameters and show renal-protective signals in high-risk populations.

The primary goal for a patient like Tony is to lower his A1C and postprandial glucose. Still, the added benefits of weight loss and cardiovascular protection make GLP-1 agonists a far superior choice over prandial insulin. The weight loss itself helps improve insulin sensitivity, creating a positive feedback loop for better glycemic control.

Cardiovascular Outcome Trials: LEADER, REWIND, SUSTAIN, PIONEER, FLOW, and SURPASS

The transformation in diabetes management is anchored in evidence that some GLP-1 RAs reduce major adverse cardiovascular events (MACE) beyond glycemic control.

• LEADER (liraglutide):

• • Population: high cardiovascular risk; ~81% with established disease.
  • Outcome: significant reduction in MACE, cardiovascular death, and all-cause mortality (Marso et al., 2016).
  • Clinical meaning: robust cardioprotection in secondary prevention populations.

• REWIND (dulaglutide):

• • Population: mixed risk with lower baseline CVD; aimed at primary prevention
  • Outcome: reduction in MACE despite fewer baseline events (Gerstein et al., 2019).
  • Clinical meaning: supports use even when CVD is not yet established, aligning with prevention strategies.

• SUSTAIN 6 (semaglutide):

• • Population: many with established CVD.
  • Outcome: consistent MACE risk reduction and strong glycemic/weight effects (Marso et al., 2016).

• PIONEER (oral semaglutide):

• • Also demonstrated MACE risk reduction and strong glycemic/weight effects (Davies et al., 2019).

• FLOW (semaglutide renal outcomes):

• • Early termination for positive renal protection signals—suggesting reduced progression of nephropathy in high-risk profiles.

• SURPASS (tirzepatide):

• • Ongoing cardiovascular outcome program; early data show potent glycemic and weight

Mechanistic hypotheses for cardiovascular protection include blood pressure reduction, weight loss, improved lipids, anti-inflammatory actions, improved endothelial function, and enhanced renal artery flow. Taken together, these findings shift care from a”glucose-only” paradigm to a cardiometabolic risk-reduction framework.

Choosing and Initiating a GLP-1 Receptor Agonist

The market now offers a variety of GLP-1 agents, each with unique characteristics.

Key GLP-1 Receptor Agonists and Their Benefits:

• Semaglutide (Ozempic, Rybelsus, Wegovy): Available as a weekly injection or a daily oral tablet. It has demonstrated robust benefits for A1C reduction, weight loss, and cardiovascular and renal protection.
• Dulaglutide (Trulicity): A weekly injection proven to reduce heart and kidney events and promote weight loss.
• Liraglutide (Victoza, Saxenda): A daily injection with established heart, kidney, and weight loss benefits.
• Tirzepatide (Mounjaro, Zepbound): A newer, powerful weekly injection that is a dual GIP/GLP-1 agonist. It has shown exceptional results in lowering A1C and weight loss.

When starting one of these medications, the principle is “start low, go slow.” We initiate treatment at the lowest possible dose to minimize gastrointestinal side effects like nausea and gradually titrate the dose upward.

Perioperative and Other Clinical Considerations

Slower gastric emptying with GLP-1 RAs increases aspiration risk during anesthesia. Therefore, we consider holding the medication 1–2 weeks prior to procedures requiring sedation, in coordination with the medical and anesthesia teams. Emerging reports of non-arteritic anterior ischemic optic neuropathy (NAION) also warrant cautious dose escalation and monitoring for vision changes. Other considerations include gallbladder issues related to rapid weight loss and pancreatitis risk, although large analyses have not shown an increased incidence.

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

Our Multidisciplinary Model in El Paso: Integrating Chiropractic, Internal Medicine, and Functional Medicine

At Injury Medical Clinic, our care model reflects the modern reality that metabolic, musculoskeletal, and behavioral health intersect. This is where the integration of our services becomes so powerful.

How We Integrate Services

• Medical Oversight (Internal Medicine):

• • Under Dr. Cardenas’s guidance, we conduct risk stratification for ASCVD, HF, and CKD, selecting GLP-1 RA or SGLT2 agents per ADA
  • She oversees monitoring for adverse effects (GI, dehydration, AKI, biliary issues, thyroid risk) and coordinates procedure prep to mitigate aspiration risk.

• Integrative Chiropractic Care:

• • My role as a chiropractor is to address spinal alignment and joint mechanics. This reduces nociceptive input and can dampen sympathetic overdrive that worsens insulin resistance.
  • Manual therapies and neuromuscular re-education improve functional movement, enhancing glucose uptake in skeletal muscle via increased GLUT4 translocation stimulated by muscle contraction.
  • I focus on low-impact loading and postural strategies to enable consistent activity, supporting the weight loss and cardiometabolic benefits of SGLT2 and GLP-1 RA therapies.

• Functional Medicine:

• • We create personalized nutrition plans that support satiety, protein adequacy, and glycemic stability while minimizing GI side effects from medications.
  • We use microbiome-aware strategies, such as promoting fiber diversity and prebiotic-rich foods, to complement gastric emptying.
  • We emphasize stress modulation through breathwork and sleep optimization to reduce cortisol levels, thereby improving insulin sensitivity and appetite regulation.

• Personal Injury and Rehabilitation:

• • For patients with musculoskeletal injuries, we tailor graded exercise to avoid setbacks while maintaining the metabolic activity crucial for weight and glycemic control.

Why Integrative Chiropractic Fits

Pain, dysfunctional movement, and autonomic dysregulation increase systemic inflammation, worsen insulin resistance, and complicate weight management. By improving biomechanics and reducing pain, patients can engage meaningfully in exercise, enhancing insulin-independent glucose disposal and mitochondrial efficiency. My clinical observations indicate that patients on GLP-1 RAs who also receive consistent manual therapy, movement retraining, and posture optimization report fewer exercise interruptions and better GI symptom management, leading to more sustained weight loss trajectories. These insights are part of my ongoing work, which I share on ChiropracticScientist.com and LinkedIn.

Clinical Case Example: Loretta

Let’s consider a real-world application. Loretta is a 72-year-old woman with a 15-year history of type 2 diabetes. Two years ago, she had a heart attack and now has two coronary stents, establishing a clear diagnosis of coronary artery disease (CAD). Her A1c is 8.1% (too high), and her kidney function is declining (eGFR of 55). She is currently on metformin and sitagliptin (Januvia), a DPP-4 inhibitor.

Based on the new guidelines, Loretta is a perfect candidate for an SGLT2 inhibitor. Adding this agent would:

1. Address Her High ASCVD Risk: Provide proven cardiovascular protection and reduce her risk of future events.
2. Protect Her Kidneys: Slow the progression of her chronic kidney disease.
3. Improve Glycemic Control: Lower her A1c by approximately 1% to bring her closer to her target.
4. Simplify Her Regimen: We could switch her to a combination pill of an SGLT2 inhibitor and extended-release metformin. This reduces pill burden, improves adherence, and is better tolerated.

By integrating this medical strategy with chiropractic care to improve her mobility and functional medicine to optimize her diet, we can provide Loretta with a comprehensive plan that not only manages her diabetes but actively protects her heart and kidneys, enhancing her quality of life for years to come.

Summary: A New Paradigm in Diabetes and Cardiometabolic Care

Today, diabetes care prioritizes cardiometabolic risk reduction, anchored in therapies with evidence of cardiovascular and renal outcomes. SGLT2 inhibitors and GLP-1 receptor agonists play a central role due to their multifaceted benefits beyond glucose lowering. An integrative, multidisciplinary approach—combining internal medicine oversight, chiropractic care, functional medicine, and rehabilitation—translates the science into sustainable outcomes. Under the guidance of Dr. Maria Guadalupe Cardenas, M.D., and our clinical team in El Paso, we tailor care to each patient, balancing efficacy, tolerability, safety, and access. With thoughtful medication management, targeted lifestyle strategies, and movement-based metabolic support, patients achieve not only better numbers but stronger hearts, kidneys, minds, and lives.

References

• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chordà, V., Chuquiure-Valenzuela, E., Conte, C., DeMets, D., Echols, O., Enríquez, A., Escobedo, J., Furtado, M. V., Goodman, S. G., Granger, C. B., Herod, P., … Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Davies, M., et al. (2019). Oral Semaglutide in Type 2 Diabetes (PIONEER Trials). New England Journal of Medicine, 381(9), 841–851.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., & Avezum, A. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): double-blind, randomized, ed placebo-controlled trial. The Lancet, 394(10193), 121–130.
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Wolden, M. L., Buse, J. B., & SUSTAIN-6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., & Committee, L. T. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., B? lohlávek, J., Bøhmer, E., Claggett, B., de Boer, R. A., Dzerova, N., Dargie, H. J., El-Khadra, Y., Eliasson, B., Fomina, I. G., Gomez-Mesa, J. E., … Langkilde, A.-M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., Matthews, D. R., & Canvas Program Collaborative Group. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657.
• American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Supplement 1).
• Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A.-M., & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347–357.
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., Inzucchi, S. E., & EMPA-REG OUTCOME Investigators. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.

SEO Tags: cardiometabolic health, type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, chronic kidney disease, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, heart failure, ASCVD, risk reduction, EMPA-REG, DAPA-HF, Jardiance, Farxiga, diabetes management, evidence-based medicine, MACE, nephroprotection, Over-basalization, Prandial Insulin, A1C, Postprandial Glucose, Weight Loss, Semaglutide, Ozempic, Mounjaro, Cardiovascular Outcome Trials, incretin effect, LEADER trial, REWIND trial, SUSTAIN 6, PIONEER, FLOW trial, SURPASS tirzepatide, DPP-4 inhibitors, obesity and satiety, gastric emptying, gallbladder risk, pancreatitis risk, acute kidney injury, thyroid cancer MEN-2, anesthesia aspiration risk, optic neuropathy, NAFLD MASH, neuroinflammation, PCOS fertility, rehabilitation, El Paso Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD